Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment

To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. Five HIV-1-inf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 1997-09, Vol.11 (11), p.F79-F84
Hauptverfasser: DE JONG, M. D, DE BOER, R. J, DE WOLF, F, FOUDRAINE, N. A, BOUCHER, C. A. B, GOUDSMIT, J, LANGE, J. M. A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page F84
container_issue 11
container_start_page F79
container_title AIDS (London)
container_volume 11
creator DE JONG, M. D
DE BOER, R. J
DE WOLF, F
FOUDRAINE, N. A
BOUCHER, C. A. B
GOUDSMIT, J
LANGE, J. M. A
description To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations. After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal. Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.
doi_str_mv 10.1097/00002030-199711000-00002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16253572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16253572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-d74c3e29075d4b484bba93bd6dd059d45548b577e53f0e227beed59412fef5ea3</originalsourceid><addsrcrecordid>eNo9kE1PwzAMhiMEGmPwE5ByQNwK-WySI5qATZq0Ax_XKm1cUdQ2I8km7d_TsTJfLNvPa1svQpiSB0qMeiRDMMJJRo1RlA5V9tc6Q1MqFM-kVPQcTQnLTWa4IpfoKsbvgZBE6wmaGE6Y4GqK3tY7CPHL-4R9jRfLz4ziXRMsdI3Ftk4QMNjQ7rFrYuX71PRbmxrfH2g7lAFS8AdBi1MAmzro0zW6qG0b4WbMM_Tx8vw-X2Sr9ety_rTKKqHzlDklKg7MECWdKIUWZWkNL13uHJHGCSmFLqVSIHlNgDFVAjhpBGU11BIsn6H7495N8D9biKnohiehbW0PfhsLmjPJpWIDqI9gFXyMAepiE5rOhn1BSXHws_j3szj5eWwN0tvxxrbswJ2Eo4HD_G6c21jZtg62r5p4wpjSXGnFfwGJGn3j</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16253572</pqid></control><display><type>article</type><title>Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><creator>DE JONG, M. D ; DE BOER, R. J ; DE WOLF, F ; FOUDRAINE, N. A ; BOUCHER, C. A. B ; GOUDSMIT, J ; LANGE, J. M. A</creator><creatorcontrib>DE JONG, M. D ; DE BOER, R. J ; DE WOLF, F ; FOUDRAINE, N. A ; BOUCHER, C. A. B ; GOUDSMIT, J ; LANGE, J. M. A</creatorcontrib><description>To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations. After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal. Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/00002030-199711000-00002</identifier><identifier>PMID: 9302437</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Anti-HIV Agents - therapeutic use ; Biological and medical sciences ; CD4 Lymphocyte Count ; HIV Core Protein p24 - analysis ; HIV Infections - drug therapy ; HIV Infections - transmission ; HIV-1 ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Indinavir - therapeutic use ; Medical sciences ; Models, Biological ; Nevirapine ; Pyridines - therapeutic use ; Risk Factors ; RNA, Viral - analysis ; Substance Withdrawal Syndrome - diagnosis ; Viral Load ; Viremia - chemically induced ; Zidovudine - therapeutic use</subject><ispartof>AIDS (London), 1997-09, Vol.11 (11), p.F79-F84</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-d74c3e29075d4b484bba93bd6dd059d45548b577e53f0e227beed59412fef5ea3</citedby><cites>FETCH-LOGICAL-c486t-d74c3e29075d4b484bba93bd6dd059d45548b577e53f0e227beed59412fef5ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2783787$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9302437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE JONG, M. D</creatorcontrib><creatorcontrib>DE BOER, R. J</creatorcontrib><creatorcontrib>DE WOLF, F</creatorcontrib><creatorcontrib>FOUDRAINE, N. A</creatorcontrib><creatorcontrib>BOUCHER, C. A. B</creatorcontrib><creatorcontrib>GOUDSMIT, J</creatorcontrib><creatorcontrib>LANGE, J. M. A</creatorcontrib><title>Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations. After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal. Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>HIV Core Protein p24 - analysis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - transmission</subject><subject>HIV-1</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Indinavir - therapeutic use</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Nevirapine</subject><subject>Pyridines - therapeutic use</subject><subject>Risk Factors</subject><subject>RNA, Viral - analysis</subject><subject>Substance Withdrawal Syndrome - diagnosis</subject><subject>Viral Load</subject><subject>Viremia - chemically induced</subject><subject>Zidovudine - therapeutic use</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PwzAMhiMEGmPwE5ByQNwK-WySI5qATZq0Ax_XKm1cUdQ2I8km7d_TsTJfLNvPa1svQpiSB0qMeiRDMMJJRo1RlA5V9tc6Q1MqFM-kVPQcTQnLTWa4IpfoKsbvgZBE6wmaGE6Y4GqK3tY7CPHL-4R9jRfLz4ziXRMsdI3Ftk4QMNjQ7rFrYuX71PRbmxrfH2g7lAFS8AdBi1MAmzro0zW6qG0b4WbMM_Tx8vw-X2Sr9ety_rTKKqHzlDklKg7MECWdKIUWZWkNL13uHJHGCSmFLqVSIHlNgDFVAjhpBGU11BIsn6H7495N8D9biKnohiehbW0PfhsLmjPJpWIDqI9gFXyMAepiE5rOhn1BSXHws_j3szj5eWwN0tvxxrbswJ2Eo4HD_G6c21jZtg62r5p4wpjSXGnFfwGJGn3j</recordid><startdate>19970901</startdate><enddate>19970901</enddate><creator>DE JONG, M. D</creator><creator>DE BOER, R. J</creator><creator>DE WOLF, F</creator><creator>FOUDRAINE, N. A</creator><creator>BOUCHER, C. A. B</creator><creator>GOUDSMIT, J</creator><creator>LANGE, J. M. A</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19970901</creationdate><title>Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment</title><author>DE JONG, M. D ; DE BOER, R. J ; DE WOLF, F ; FOUDRAINE, N. A ; BOUCHER, C. A. B ; GOUDSMIT, J ; LANGE, J. M. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-d74c3e29075d4b484bba93bd6dd059d45548b577e53f0e227beed59412fef5ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>HIV Core Protein p24 - analysis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - transmission</topic><topic>HIV-1</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Indinavir - therapeutic use</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Nevirapine</topic><topic>Pyridines - therapeutic use</topic><topic>Risk Factors</topic><topic>RNA, Viral - analysis</topic><topic>Substance Withdrawal Syndrome - diagnosis</topic><topic>Viral Load</topic><topic>Viremia - chemically induced</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE JONG, M. D</creatorcontrib><creatorcontrib>DE BOER, R. J</creatorcontrib><creatorcontrib>DE WOLF, F</creatorcontrib><creatorcontrib>FOUDRAINE, N. A</creatorcontrib><creatorcontrib>BOUCHER, C. A. B</creatorcontrib><creatorcontrib>GOUDSMIT, J</creatorcontrib><creatorcontrib>LANGE, J. M. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE JONG, M. D</au><au>DE BOER, R. J</au><au>DE WOLF, F</au><au>FOUDRAINE, N. A</au><au>BOUCHER, C. A. B</au><au>GOUDSMIT, J</au><au>LANGE, J. M. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>1997-09-01</date><risdate>1997</risdate><volume>11</volume><issue>11</issue><spage>F79</spage><epage>F84</epage><pages>F79-F84</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>To determine whether, as predicted by predator-prey dynamics, early withdrawal of antiretroviral therapy, i.e. when the number of CD4+ lymphocytes is still elevated, results in an overshoot of HIV-1 viraemia due to infection of increased numbers of available target cells at that time. Five HIV-1-infected individuals were identified who discontinued antiretroviral therapy for various reasons after 8-19 days, and from whom stored serum samples obtained before, during, and shortly after treatment were available for measurement of HIV-1 RNA load. A mathematical model was designed to assess whether increased target cell availability could quantitatively explain the clinical observations. After therapy withdrawal, increases in the HIV-1 RNA load to levels exceeding pretreatment values by log10 0.6-1.5 copies/ml were observed after 2-17 days in all four of the individuals who had treatment-induced increases in CD4+ cell counts at the time of therapy withdrawal. Increases in viraemia were maximal within a few days, and subsequently seemed to wane until the pretreatment equilibrium between virus and its target cells was attained. Mathematical modelling confirms that these transient increases in viraemia can be explained by increased availability of target cells at the time of therapy withdrawal. Transient rises in HIV-1 viraemia do occur following early therapy withdrawal. These rises especially warrant consideration in short-term antiretroviral regimens for prevention of mother-to-child transmission, as are being studied in developing countries, since they could result in an increased transmission risk during the post-partum period through breast-feeding. This possibility needs to be investigated urgently.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>9302437</pmid><doi>10.1097/00002030-199711000-00002</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-9370
ispartof AIDS (London), 1997-09, Vol.11 (11), p.F79-F84
issn 0269-9370
1473-5571
language eng
recordid cdi_proquest_miscellaneous_16253572
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload
subjects Anti-HIV Agents - therapeutic use
Biological and medical sciences
CD4 Lymphocyte Count
HIV Core Protein p24 - analysis
HIV Infections - drug therapy
HIV Infections - transmission
HIV-1
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Indinavir - therapeutic use
Medical sciences
Models, Biological
Nevirapine
Pyridines - therapeutic use
Risk Factors
RNA, Viral - analysis
Substance Withdrawal Syndrome - diagnosis
Viral Load
Viremia - chemically induced
Zidovudine - therapeutic use
title Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A51%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overshoot%20of%20HIV-1%20viraemia%20after%20early%20discontinuation%20of%20antiretroviral%20treatment&rft.jtitle=AIDS%20(London)&rft.au=DE%20JONG,%20M.%20D&rft.date=1997-09-01&rft.volume=11&rft.issue=11&rft.spage=F79&rft.epage=F84&rft.pages=F79-F84&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/00002030-199711000-00002&rft_dat=%3Cproquest_cross%3E16253572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16253572&rft_id=info:pmid/9302437&rfr_iscdi=true